Fannie Mae, Freddie Mac shares tumble after conservatorship comments
BUDAPEST - Hungarian pharmaceutical company Gedeon Richter (BUD:RICHTER) reported first quarter revenue in line with expectations and higher-than-anticipated profit, while reaffirming its full-year outlook. The company’s shares edged up 0.5% following the announcement.
Gedeon Richter’s Q1 sales reached HUF 224.0 billion, aligning with analyst consensus. Total (EPA:TTEF) pharmaceutical revenues grew 10% YoY, or 6% at constant exchange rates (CER), falling short of the company’s full-year guidance of 10% CER growth. The slower start was attributed to high comparables in the Women’s Healthcare segment, which saw just 3% YoY growth at CER in Q1.
Clean EBIT for the quarter increased 7% YoY to HUF 68.5 billion, slightly below consensus estimates. However, net profit surpassed expectations by 9%, boosted by a stronger-than-expected net financial result. The company’s CNS, Biotechnology, and General Medicine segments all achieved double-digit growth during the period.
Despite the slower Q1 growth, Gedeon Richter maintained its full-year 2025 guidance, projecting 10% CER growth in pharmaceutical revenues and clean EBIT. The company anticipates growth to accelerate in the second half of the year.
"We remain confident in our ability to meet our full-year targets as we expect growth to pick up in the latter half of 2025," said a company spokesperson.
Gedeon Richter recently outlined its 10-year plan for 2025-35, detailing strategies to navigate the US Vraylar patent expiry in 2029 and improve its base business EBIT margin from 8% in 2024 to over 20% by 2035.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.